University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer : A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel

dc.contributor.authorRobinson, Richard
dc.contributor.authorMarconi, Lorenzo
dc.contributor.authorMacPepple, Ekelechi
dc.contributor.authorHakenberg, Oliver W.
dc.contributor.authorWatkin, Nick
dc.contributor.authorYuan, Yuhong
dc.contributor.authorLam, Thomas
dc.contributor.authorMacLennan, Steven
dc.contributor.authorAdewuyi, Temitope E.
dc.contributor.authorCoscione, Alberto
dc.contributor.authorMinhas, Suks S.
dc.contributor.authorCompérat, Eva M.
dc.contributor.authorNecchi, Andrea
dc.contributor.institutionUniversity of Aberdeen.Academic Urology Uniten
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2019-04-23T23:03:50Z
dc.date.available2019-04-23T23:03:50Z
dc.date.embargoedUntil2019-04-24
dc.date.issued2018-07
dc.descriptionRichard Robinson certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Dr. Thomas Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Mr. Suks S. Minhas receives company speaker honorarium for Lilly and has received a fellowship/medical travel grant from American Medical systems Fellowship. Dr. Andrea Necchi is a company consultant for and has received company speaker honoraria from Bayer and Astra Zeneca, and has received a fellowship/medical travel grant from Pierre Fabre; he has been involved with trial participation for Roche, Merck Sharp & Dohme, BMS, and Novartis, as well as receiving grants/research supports from GlaxoSmithKline and Millenium. Oliver Hakenberg, Nick Watkin, Richard Robinson, Yuhong Yuan, Ekelechi MacPepple, Temitope E. Adewuyi, Steven MacLennan, Alberto Coscione, and Eva M. Compérat have nothing to declare.en
dc.description.statusPeer revieweden
dc.format.extent8
dc.format.extent348636
dc.identifier118587279
dc.identifierc73ebcd6-860e-45d6-9995-b5e712040898
dc.identifier85046134700
dc.identifier.citationRobinson, R, Marconi, L, MacPepple, E, Hakenberg, O W, Watkin, N, Yuan, Y, Lam, T, MacLennan, S, Adewuyi, T E, Coscione, A, Minhas, S S, Compérat, E M & Necchi, A 2018, 'Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer : A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel', European Urology, vol. 74, no. 1, pp. 76-83. https://doi.org/10.1016/j.eururo.2018.04.003en
dc.identifier.doi10.1016/j.eururo.2018.04.003
dc.identifier.iss1en
dc.identifier.issn0302-2838
dc.identifier.otherORCID: /0000-0002-2691-8421/work/61024721
dc.identifier.urihttp://hdl.handle.net/2164/12211
dc.identifier.vol74en
dc.language.isoeng
dc.relation.ispartofEuropean Urologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectpenile canceren
dc.subjectadjuvant radiotherapyen
dc.subjectlymph nodesen
dc.subjectR Medicine (General)en
dc.subject.lccR1en
dc.titleRisks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer : A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panelen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Risks_and_benefits_of_ART_after_ILND_Re_submission_clean_combined_file.pdf
Size:
340.46 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
8.31 KB
Format:
Plain Text
Description: